使用FAERS数据库对萨库比特里尔/瓦尔萨坦和瓦尔萨坦之间的不良事件进行比较分析:不成比例性分析
Da Li1,2, Yunfeng Li1, Lei Yao1
1Department of Cardiology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
萨库比特里尔/瓦尔萨坦和瓦尔萨坦在心血管治疗中表现出不同的不良事件概况. 需要进一步的研究来证实这些心力衰竭和高血压管理的安全性发现.
科学领域:
- 心血管药理学心血管药理学
- 药物监督 药物监督 药物监督
- 药物安全分析 药物安全分析
背景情况:
- 萨库比特里尔/瓦尔萨坦和瓦尔萨坦是治疗心力衰竭和高血压的关键药物.
- 对优化临床监测进行比较安全分析至关重要.
研究的目的:
- 为了比较sacubitril/valsartan和valsartan之间的不良事件 (AE) 信号.
- 确定与这些心血管药物相关的差异性安全风险.
主要方法:
- 从2004Q1到2024Q2使用了FDA不良事件报告系统 (FAERS) 数据库.
- 采用不成比例分析和贝叶斯方法来检测和评估AE信号.
主要成果:
- 分析了sacubitril/valsartan的102,678份报告与瓦尔萨坦的24,318份报告.
- 萨库比特里尔/瓦尔萨坦与心脏疾病有很强的联系 (ROR 4.13),而瓦尔萨坦与血管疾病有关 (ROR 2.67).
- 鉴定了sacubitril/valsartan的意想不到的副作用 (例如,心肌梗塞,心律失常,流体失衡) 和 valsartan的独特副作用 (例如,对疾病的恐惧,血栓性中风).
结论:
- 萨库比特里尔/瓦尔萨坦和瓦尔萨坦呈现出不同的不良事件概况.
- 强调需要对萨库比特里尔进行大规模临床试验和机制研究,以验证观察到的安全信号.
更多相关视频
06:04Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Hazard Ratio
For example, in a clinical trial...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Comparing the Survival Analysis of Two or More Groups
Bioequivalence studies: Biowaivers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
